Koers Biovica International AB (publ) Nasdaq Stockholm
Aandelen
SE0008613731
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 10 mln. 938K 864K | Omzet 2025 * | 116 mln. 10,88 mln. 10,03 mln. | Marktkapitalisatie | 151 mln. 14,13 mln. 13,02 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -115 mln. -10,78 mln. -9,94 mln. | Nettowinst (verlies) 2025 * | -60 mln. -5,63 mln. -5,19 mln. | EV/omzet 2024 * | 7,71 x |
Nettoliquiditeiten 2024 * | 73,52 mln. 6,89 mln. 6,35 mln. | Nettoliquiditeiten 2025 * | 45,95 mln. 4,31 mln. 3,97 mln. | EV/omzet 2025 * | 0,9 x |
K/w-verhouding 2024 * |
-0,24
x | K/w-verhouding 2025 * |
-0,63
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,54% |
Recentste transcriptie over Biovica International AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anders Rylander
CEO | Chief Executive Officer | 54 | 01-01-10 |
Anders Morén
DFI | Director of Finance/CFO | 59 | 01-01-23 |
Hanna Ritzen
CTO | Chief Tech/Sci/R&D Officer | 45 | 01-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 64 | 20-03-19 | |
Annika Berg
BRD | Director/Board Member | 61 | 01-01-20 |
Maria Holmlund
BRD | Director/Board Member | 68 | 01-01-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-32,63% | 9,2 mld. | |
-5,66% | 3,12 mld. | |
-18,33% | 2,05 mld. | |
-24,39% | 1,59 mld. | |
+65,65% | 1,44 mld. | |
+32,83% | 830 mln. | |
-6,77% | 720 mln. | |
-29,80% | 507 mln. | |
+0,40% | 297 mln. |